Mabpharm Limited (2181) AI Stock Analysis

• Market Cap: HK$2.06B
• Dividend Yield: N/A
• Average Volume (3M): 65.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.36
• Revenue Growth: 190.48%
• EPS Growth: 40.11%
• Country: HK
• Employees: 315
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 4,124,080,000
• 10 Day Avg. Volume: 120,600
• 30 Day Avg. Volume: 65,733
• PEG Ratio: -0.26
• Price to Book (P/B): 15.60
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -24.52
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$0.50
• Price Target Upside: 0.00%
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: HK$0.50 ▲(0.00%Upside)

The low overall stock score is primarily due to financial instability and negative cash flows, which highlight significant financial risks. Technical analysis provides a neutral outlook with no strong momentum indicators, while valuation metrics reflect ongoing losses.

Mabpharm Limited Business Overview & Revenue Model

Company Description

Mabpharm Limited, a biopharmaceutical company, engages in research, development, and production of drugs and biosimilar drugs for allergic diseases, cancers, and autoimmune diseases in China. Its products under the Phase III clinical trial include CMAB007, a recombinant humanized anti-IgE monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for moderate to severe active rheumatoid arthritis; and CMAB807 for osteoporosis indications. The company is also developing CMAB819 that is in Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X for the treatment of tumor bone metastasis; and CMAB809 that is in Phase I clinical trial for the treatment of HER2 overexpressing breast cancer and metastatic gastric cancer. In addition, its products under the pre-clinical stage include CMAB810 for the treatment of breast cancer; CMAB816 for the treatment of periodic fever syndrome, lung cancer, and systemic juvenile idiopathic arthritis; CMAB017 for the treatment of KRAS wild-type colorectal cancer; CMAB015, a biosimilar candidate for secukinumab to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; CMAB018, a biosimilar candidate for mepolizumab, for the treatment of asthma and eosinophilic granulomatous polyangiitis; and CMAB022 for the treatment of inflammatory diseases. The company also involved in research and development, technical consulting, technology transfer, and technical services of biological products, diagnostic reagents, chemical biological reagents, and drugs. The company was incorporated in 2018 and is headquartered in Taizhou, the People's Republic of China.

How the Company Makes Money

Mabpharm Limited generates revenue through the development and commercialization of its proprietary monoclonal antibody drugs. The company's key revenue streams include sales of its therapeutic products to healthcare providers and institutions, as well as collaborations and licensing agreements with other pharmaceutical companies. These partnerships often involve upfront payments, milestone payments, and royalties based on product sales. Additionally, Mabpharm Limited may receive government grants and financial support for research and development activities, contributing to its overall earnings.

Mabpharm Limited Financial Statement Overview

Summary

Mabpharm Limited has shown significant revenue growth but continues to face profitability and financial stability challenges. High leverage, negative cash flows, and consistent losses indicate potential financial risks.

Income Statement

Mabpharm Limited has shown significant revenue growth of 196.24% from the previous year, indicating strong top-line expansion. However, the company remains unprofitable with a negative net profit margin of -49.55% and a negative EBIT margin of -46.34%. Despite the improvement in revenue, consistent losses over the years indicate challenges in achieving profitability.

Balance Sheet

The company exhibits a high debt-to-equity ratio of 3.50, reflecting substantial leverage and potential financial risk. The return on equity is negative at -143.89%, aligning with ongoing net losses. The equity ratio of 8.75% suggests limited equity as a proportion of total assets, further emphasizing financial instability.

Cash Flow

Mabpharm Limited's cash flow statements reveal challenges with cash generation, as evidenced by the absence of free cash flow and operating cash flow for the current period. Historical free cash flow has been negative, indicating ongoing cash management issues. The inability to generate positive operating cash flow relative to net income further highlights the need for operational improvements.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	258.23M	87.16M	55.92M	82.88M	0.00
Gross Profit	219.39M	75.24M	40.54M	66.11M	0.00
EBITDA	-67.81M	-139.08M	-152.08M	-245.46M	-169.93M
Net Income	-127.95M	-209.36M	-210.62M	-294.22M	-188.57M
Balance Sheet
Total Assets	1.02B	1.03B	917.52M	899.90M	1.16B
Cash, Cash Equivalents and Short-Term Investments	89.34M	173.34M	48.61M	81.56M	484.85M
Total Debt	293.09M	260.07M	126.34M	45.69M	40.35M
Total Liabilities	927.28M	829.92M	516.58M	297.92M	281.55M
Stockholders Equity	88.93M	205.06M	400.94M	601.98M	881.49M
Cash Flow
Free Cash Flow	-63.58M	38.35M	-182.01M	-348.14M	-344.47M
Operating Cash Flow	-4.10M	57.39M	-56.88M	-199.47M	-147.23M
Investing Cash Flow	-98.20M	-3.50M	-104.95M	-179.42M	156.00M
Financing Cash Flow	18.28M	85.60M	112.26M	-17.78M	-80.48M

Mabpharm Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2181, the sentiment is Positive. The current price of 0.5 is above the 20-day moving average (MA) of 0.49, above the 50-day MA of 0.47, and above the 200-day MA of 0.39, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 56.75 is Neutral, neither overbought nor oversold. The STOCH value of 17.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2181.

Mabpharm Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	65 Neutral	HK$1.49B	36.75	4.92%	―	38.48%	―
Sector *	52 Neutral	$7.53B	0.20	-63.81%	2.31%	16.15%	0.40%
3681	50 Neutral	HK$2.40B	―	-75.64%	―	42.21%	29.52%
6996	45 Neutral	HK$1.93B	―	-31.66%	―	30.54%	48.43%
2181	42 Neutral	HK$2.06B	―	-86.56%	―	190.48%	40.11%
6978	37 Underperform	HK$1.85B	―	-228.99%	―	―	44.88%
2185	32 Underperform	HK$1.57B	―	-12.49%	―	―	50.94%

Mabpharm Limited Corporate Events

Mabpharm Limited Announces Unanimous Approval of AGM Resolutions

Mabpharm Limited announced that all proposed resolutions at its Annual General Meeting held on June 18, 2025, were passed unanimously by shareholders. These resolutions included the re-election of directors, the re-appointment of auditors, and the granting of mandates to the board for share repurchase and issuance. The successful passing of these resolutions reflects strong shareholder support and positions the company for continued strategic growth and operational stability.

Mabpharm Limited Announces 2025 Annual General Meeting and Share Repurchase Proposal

Mabpharm Limited has announced its upcoming Annual General Meeting (AGM) scheduled for June 18, 2025, in Shanghai. Key agenda items include the consideration of the company’s audited financial statements for 2024, re-election of several directors, re-appointment of Ernst & Young as auditors, and a proposal to authorize the company to repurchase up to 10% of its issued shares. This announcement reflects the company’s ongoing governance and strategic financial management, potentially impacting shareholder value and market confidence.